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ABSTRACT  
A series of some novel N-Mannich bases of heterocyclic 1,3,4-thiadiazole were synthesized through the condensation reaction of 1,3,4-
thiadiazole containing a aromatic secondary amine, aromatic aldehydes and cyclic compounds employing Mannich reaction and usi ng 
conventional synthesis. All the synthesized compounds were obtained in the range of 57.41-83.3 % yield. The structures of synthesized 
compounds were confirmed by UV, IR, 1H NMR spectroscopy. the essential structural features responsible for interaction with receptor site are 
established within a suggested pharmacophore. The in vitro antibacterial activity of the synthesized compounds was determined, against two 
Gram-positive bacteria, viz. S. aureus & B. subtilis and Gram-negative, viz. E. coli and K. pneumoniae, by cup-plate method using the standard 
drug ciprofloxacin. Minimum inhibitory concentrations (MIC) changed in the range of 1.56_ _ 200 mg mL_1. Compound 3b exhibited excellent 
activity against both bacteria. The in vitro antifungal activity of the synthesized compound was also evaluated by cup-plate method against the 
fungi A. niger and C. albicans compared with the standard drug Fluconazole. Compound 4a, 8a exhibited excellent activity against both fungi. 
The result has shown that the compounds are quite active against pathogens under study and were nontoxic. The anti-inflammatory activity of 
the compound was evaluated, on albino rats, by carageenan induced rat paw oedema method using the standard drug diclofenac so dium. 
Compound 7b and 8c exhibited excellent anti-inflammatory and analgesic pharmacological activities. Structurally the compound 7b has a 
greater number of unsaturated hydrocarbons in schiff base, which shows good lipophilic properties within electron rich morpho line ring in 
Mannich base. Statistical significance of differences between group was determined by one-way analysis of variance (ANOVA). Among the 
synthesized compounds 3a, 4b, 5c, 7b, 8a and 8c were found be the most active. All the synthesized compounds were found to be  low lethal as 
ascertained by LD50 test. 
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Introduction 
A lot of research has been done on N-Mannich bases 
derivatives and more research is going on in present time. 
From the literature it was concluded that the derivatives of 
N-Mannich bases of 1,3,4-thiadiazole shown diver type of 
activities viz antimicrobial, anti-inflammatory activities. 
Furthermore N-Mannich bases of 1,3,4-thiadiazole which 
contain an azomethine group attract much interest due to 
their synthetic along with antitumor (Dhapalapur MG et 
al.,1968) antimycobacterial (Patole J et al., 2006) 
antihypertensive (Turner S et al., 1988, Turner S et al., 
1988), properties. The thiadiazole nucleus with N-C-S 
linkage exhibits a large number of biological activities 
(Kurtzer F et al., 1965). The treatment of microbial 
infections, especially bacterial infection, has become an 
important problem to solve due to the emergence of 
mulidrug resistance. As a contribution to the new 
antibacterial drug development we have previously 
synthesized N-Mannich bases of 1,3,4-thiadiazole 
derivatives. The aim of this study was to synthesize some N-
Mannich bases having inhibition against microbial infections. 
An additionally anti-inflammatory activity was evaluated.  
The interesting properties of many of these heteroccycles 
have increased the need for rapid synthesis of new, 
potentially useful sulfur-nitrogen containing heterocycles. 
Chemistry 
A lone pair of electrone is present on nitrogen atom. 1,3,4-
thiadiazole is a weak base. Electrone density on the nitrogen 
atom and facilitative reaction undergoes with eletrophilic 
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reagents. It has a common structure, ie  
 which may consist of an 
aromatic secondary amine of 1,3,4-thiadiazole ring, a thionyl 
carbon (none of the valencies of which is satisfied by 
hydrogen) asa thiosemicarbazide and Schiff base between 
the flat carbon (-N=CH-). From the considerations of the 
above facts , it was planned to synthesize Mannich bases of 
1-substituted-4-(4-(phenylamino)phenyl)-1,3,4-thiadiazole-
2-yl)thiosemicarbazide by carrying out reaction between 1-
substituted-4-(5-(4-(phenylamino)phenyl)-1,3,4-thio 
diazole-2-yl)thiosemicarbazide,formaldehyde and dimethyl 
amine, morpholin, piperidine. 
Basic moiety 4-(5-(4-(phenylamino) phenyl)-1,3,4-thio 
diazol-2-yl)thiosemicarbazide (1) was synthesized from 5-(-
4-(phenylamino)phenyl)-1,3,4-thiodiazole-2-amine, into 
their corresponding carbon disulphide in presence of 
alcoholic NaOH TO obtain the sodium salts, followed by the 
addition of the hydrazine hydrate gives the 
thiosemicarbazide compound, which involved the reported 
reaction mechanism of Nucleophilic Addition Reaction 
(Ananthanaryan R et al., 2005). Further derivatives of 
methylene-4-(5-(-(phenylamino) phenyl-1,3,4-thiadiazol-2-
yl)thiosemicarbazide 2(a-f), were synthesized by 4-(-5-(4-(-
phenylamino)phenyl-1,3,4-thiadiazol-2-
yl)thiosemicarbazide and different aromatic  and 
heterocycle aldehydes. Reaction mechanism of this step 
undergoes Nucleophilic Addition Reaction (Morrison R T rt 
al., 2005). Title compounds 3(a-c), 4(a-c), 5(a-c), 6(a-c), 
7(a-c), 8(a-c) derivatives of N-Mannich bases of heterocyclic  
1,3,4-thiadiazol were prepared from 1-R1Substituted-4-(5-
(4-(phenylamino)phenyl)-1,3,4)thiosemicarbazide and 
formaldehyde, dimethylamine, morpholine, piperidine. 
Reaction mechanism of this step undergoes N-Mannich Base 
Reaction (Agarwal O P, 2006). Mannich reaction is an 
approach to bring about condensation between a compound 
containing atleast one active hydrogen ayom , formaldehyde 
and ammonia or a primary amine or a econdary amine. An 
example of Mnnich reaction is reaction between 
acetophenone or another aryl amino [(diphenyl amine) 
compound containing active hydrogen], formaldehyde and 
secondary amine (Adam R., 1996). 
MATERIALS AND METHODS 
Preparation of 4-(5-(4-(phenylamino)phenyl)-1,3,4-
thiadiazol-2-yl)thiosemicarbazide (1) 
3.76g (0.014mol) 5-(4-(phenylamino) phenyl)-1,3,4-thia 
diazol-2-amine was taken in 15ml of dimethylformamide 
(DMF) in a flat bottom flask. To this sodium hydroxide 
(0.014mol), carbon disulphide(0.014mol) were added. The 
mixture was stirred at 15-200C for 1h, to the stirred mixture 
was added hydrazine hydrate (0.014mol) and stirred 
continue for 1 h more at 600C. On adding water, a pale-
yellow solid separated out which was recrystallized from 
DMF-Ethanol. The pale yellow coloured product obtained, 
yield 78%, melting point 2510C and calculated Rf 0.72 
(Pandeya S N, et al., 1999). 
Derivatives of methylene- 4-(5-(4-(phenylamino) 
phenyl)-1,3,4-thiadiazol-2-yl)thiosemicarbazide 2(a-f) 
In a dry flat bottom flask 3.42g 4-(5-(4-(phenylamino) 
phenyl)- 1,3,4-thiadiazole-2-yl)thiosemicarbazide was taken 
in 35ml of ethanol. This solution was added an equimolar 
quantity of the appropriate different aromatic and 
heterocyclic aldehydes in a small quqntity of alcohol. Then 
added a few drops of glacial acetic acid, stirring was done for 
5 min. Immediate precipitation occurred and solid was 
filtered, dried and recrystellized from hot ethanol. The white 
powder product obtained, yield 73%, melting point 2430C 
andclculated Rf 0.68 (Yogeeswari Pet al.,2004). 
Synthesis of N-Maanich bases of heterocyclic 1,3,4-
thiadiazol derivatives, 3(a-c), 4(a-c), 5(a-c), 6(a-c), 7(a-
c), 8(a-c) (Pandeya S N et al.,1999). 
Preparation of 4-(5-(4-(N-(substituted) methyl)-N-
phenyl amino) phenyl)- 1,3,4-thiadiazol- 2-yl)-1-
benzylidene thiosemicarbazide(3a-c) 
2.44g (0.005mol) 1-benezylidene-4-(5-(4-(phenylamino) 
phenyl)-1,3,4-thiadiazol-2-yl)thiosemicarbazide was placed 
in a 250ml round bottom flask in 8ml tetrahydronfuran. To 
this solution was added 2ml formaldehyde and 2-3 drops of 
concentrated hydrochloric acid. To this mixture (0.005mol) 
dimethylamine, morpholine and piperidine(a-c) were added 
with cooling and shaking respectively. The reaction mixture 
was allowed to stand at room temperature for 1hr with 
occasional shaking, after which it was warmed on a steam 
bath for 15 min. At the end of the period, the contents were 
cooled and the product obtained was recrystallized with 
choloroform: petroleum ether (50:50). Synthesized 
compounds (3a-c)were obtained with yield 64.2%, 72.7% 
and 68.4% respectively. The colored product observed, 
melting point 2410C and calculated Rf 0.74. 
Preparation of 1-(o-hydroxybenzylidene)-4-(5-(4-(N-
(substituted)-N-phenylamino)phenyl)-1,3,4-thiadiazol-
2-yl)thiosemecarbazide(4a-c) 
2.23g (0.005mol) 1-(o-htdroxybenzylidene)-4(5-(4-(phenyl 
amino) phenyl)-1,3,4-thiadiazol-2-yl) thiosemecarbazide 
was placed in a 250ml round bottom flask in 8 ml 
tetrahydrofuran. To this solution was added 2ml 
formaldehyde and 2-3 drops of concentrated hydrochloric 
acid. To this mixture (0.005mol) dimethylamine, morpholine 
and piperidine (a-c) were added with cooling and shaking 
respectively. The reaction mixture was allowed to stand at 
room temperature for 1hr with occasional shaking, after 
which it was warmed on a steam bath for 15 min. At the end 
of the period, the contents were cooled and the product 
obtained was recrystallized with chloroform : petroleum 
(50:50). Synthesized compounds(4a-c)were obtained with 
yield 57.41%, 66.7% and63.6%respectively. The colourless 
product observed, melting point 2300C and calculated Rf 
0.54. 
Preparation of 1-(4-chlorobenzylidene)-4-(5-(4-(N-
(substituted) methyl)-N-phenylamino)phenyl)-1,3,4-
thia diazol-2-yl) thiosemecarbazide(5a-c) thiadiazol-2-
yl) thiosemecarbazide(5a-c) 
2.32g (0.005mol) 1-(4-chlorobenzylidene)-4-(5-(4-(phenyl 
amino) phenyl)-1,3,4-thiadiazol-2-yl)thiosemecarbazide was 
placed in 250ml round bottom flask in 8ml tetrahydrofuran. 
To this solution was added 2ml formaldehyde and 2-3 drops 
of concentrated hydrochloric acid. To this (0.005mol) 
dimethylamine, morpholine and piperidine (a-c) were added 
with cooling and shaking respsctively. The reaction mixture 
was allowed to stand at room tempersture for 1hr with 
occasional shaking, after which it was warmed on the steam 
bath for 15min. At the end of the period, the contents were 
cooled and the product obtained was recrystallized with 
chloroform: petroleum (50:50). Synthesized compounds 
95A-C0were obtained with yield 58%, 65.4% and 61.6% 
respectively. The colourless product observed, melting point 
2400c and calculated Rf 0.46. 
 
Sharma et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):220-228 
ISSN: 2250-1177                                                                                  [222]                                                                                 CODEN (USA): JDDTAO 
Preparation of 1-(4-(dimethylamino) benzylidene)-4-(5-
(4-(N-substituted)methyl)-N-phenylamino) 
phenyl)1,3,4-thiadiazol-2-yl)thiosemicarbazide(6a-c) 
2.37g 0.005mol 1-(4-(dimethylamino) benzylidene)-4-(5-(4-
(phenylamino) phenyl)-1,3,4-thiadiazol-2-yl) thiosemi 
carbazide was placed in 250ml round bottm flask in 8ml 
tetrahyrofurane. To this solution was added 2ml 
formaldehyde and 2-3 drops of concentrated hydrochloric 
acid. To this (0.005mol) dimethylamine, morpholine and 
piperidine (a-c) were added with cooling and shaking 
respectively. The reaction mixture was allowed to stand at 
room temperature for 1hr with occasional shaking, after 
whicw it was warmed on a steam bath for 15min. At the end 
of the period, the contents were cooled and the product 
obtained was recrystallized with chloroform: petroleum 
(50:50). Synthesised compounds (6a-c)were found with 
yield 69.8%, 73.7% and 70% respectivele. T he white 
crystalline product observed, melting point 2430C and 
calculated Rf 0.63. 
Preparation of 4-(-5-(4-(N-(substituted)methyl)-N-
phenylamino)phenyl)-1,3,4-thiadiazol-2-yl)-1-(3-
phenylallylidene)thiosemicarbazide (7a-c) 
2.28g (0.005mol) 1-(3-phenylallylidene)-4-(5-(4-(phenyl 
amino)phenyl)-1,3,4-thiadiazol-2-yl)thiosemicarbazide was 
placed in a round bottom flask in 8ml tetrahydrofuran. To 
this solution was added 2ml formaldehyde and 2-3 drops of 
concentrared hydrochloric acid. Tot this (0.005mol) 
dimethylamine, morpholie and piperiden (a-c) were added 
with cooling and shaking respectively. The reaction mixture 
was allowed to stand at room temperature for 1hr with 
occasional shaking, after which it was warmed on steam 
bath for 15min. At the end of the period, the contents were 
cooled and the product obtained was recrystallized with 
chloroform: petroleum (50:50). Synthesised compounds (7a-
c) were obtained with yield 75%, 76.8% and 74% 
respectively. The pale yellow product observed, melting 
point 2270C and calculated Rf 0.71. 
Preparation of 4-(5-(4-(N-(substituted) methyl-N-phenyl 
amino) phenyl)-1,3,4-thiadiazol-2-yl)-1-(furan-2-yl) 
methylene) thiosemicarbazide (8a-c) 
2.10g (0.005mol) 1-(furan-2-yl)methylene)-4-(5-(4-(phenyl 
amino)phenyl)-1,3,4-thiadiazol-2-yl)thiosemicarbazide was 
placed in round bottom flask in 8ml tetrahydrofuran. TOthis 
solution was added 2ml formaldehyde and 2-3 drops of 
concentrated hydrochloric acid. To this (0.005mol) 
dimethylamine, morpholine and piperidine (a-c)were added 
with cooling and shaking respectively. The reaction mixture 
was allowed to stand at room temperature for 1hr with 
occasional shaking, after which it was warmed on a steam 
bath for 15min. At the end of the period, the contents were 
cooled and the product obtained was recrystallized with 
chloroform : petroleum (50:50). Synthesised compounds 
(8a-c) were obtained with yield 78.8%, 83.3% and 79.6% 
respectively. The colouless product observed, melting point 
2490C and calculated Rf 0.59. 
 
Fig. 1 Graphical abstract of synthesized title compounds. 
 
a 
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                                                                                         c 
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4-(5-(4-(N-phenyl-N-(R2-substituted)methylamino)phenyl)-1,3,4-thiadiazol-2-yl)-1-R1-substituted-thiosemicarbazide, 3(a-c), 
4(a-c), 5(a-c), 6(a-c), 7(a-c), 8(a-c). 
COMPOUND R1 R2 
a b C 
3 C6H5 N(CH3)2 
  
4 o-C6H4-OH N(CH3)2 
  
5 p-C6H4-Cl N(CH3)2 
  
6 p-C6H4-N(CH3)2 N(CH3)2 
  
7 CH=CH-C6H5 N(CH3)2 
  
8 C4H3O* N(CH3)2 
  
*Furan      (a) NaOH, DMF, CS2, NH2NH2.H2O, 600C. (b) Aromatic aldehydes, Few drops CH3COOH, C2H5OH. (c) Tetrahydrofuran, Formaldehyde, 
concentrated hydrochloric acid, Dimethylamine, Morpholine and Piperidine (a-c), Room temperature for 1hr. 
 
Characterization of the synthesized compounds 
Synthesised compounds N-Mannich bases of heterocyclic 
1,3,4-thiadiazol derivatives 3(a-c), 4(a-c), 5(a-c), 6(a-c), 
7(a-c), 8(a-c) were synthesized by the reaction between 1-
R1Substituted-4-(5-(4-(phenylamino)phenyl)-1,3,4-
thiadiazol-2-yl)thiosemicarbazide and formaldehyde, 
dimethylamine, morpholine, piperidine using reported 
method. All melting points (m.p) were determined in open 
capillary method using Jindal point apparatus and were 
uncorrected.The purity of the compounds was routinely 
checked by thin layer chromatography (TLC) using silica gel 
G (Merck). The instruments used for spectroscopy data are 
FTIR : Bruker tensor-27 spectrophotometer (ATR) with 
diffuse reflectance method. H1NMR :JEOL GSX-400, 60MHz 
spectrometer in CDCl3, TMS (tetra methyl silane) as an 
internal standard. H1NMR and IR spectra were consistent 
with the assigned structure. The results obtain which are 
shown in table 1 indicates, derivatives of N-Mannich bases of 
heterocyclic 1,3,4-thiadiazol 3(a-c), 4(a-c), 5(a-c), 6(a-c), 
7(a-c), 8(a-c) were synthesized under conventional method 
under reaction suitable conditions. All compounds were 
conformed to the structures envisaged. Thermodynamics 
properties, physic-chemical properties and costant are given 
table 2and 3D structure of syhthesised title compounds are 
shown fig 2. 
 
Table 1 Characterization of synthesized compounds. 
Compound 
name 
Specroscopic data 
3(a-c) IR ATR (cm-1)= 3340(N-H), 3004(Ar.C-H), 2910(Ali-c-h), 1576(C=N), 1667(C-N), 1497(N-N), 104(C==S); 1H-NMR 
(DMSO-d6,  ppm): 2.5(s, 2H, NH), 6.6-6.8(m, 9H, CH, Ar-H, DEPHENYLAMINE), 7.0-7.8(m, 5H, CH, Ar-H, C6H5); Electron 
absorption spectra (UV)  max 296.76(methanol) 
4(a-c) IR ATR(CM-1)=3390(N-H),3105(Ar.C-H),2878(Ali-C-H),1560(C=N),1650(C-N), 1524(N-N),1214(C-S);1H-NMR(DMSO-
d6,δppm):2.1(s,2H,NH),2.6(s,1H,Ar-OH),6.8-6.99(m,9H,CH,Ar-H,diphenylamine),7.0-7.8(m,4H,Ar-H,C6H4),8.0-
8.7(s,1H,CH,α- to C6H4-OH);Electron absorption spectra (UV)λmax 328 (methanol). 
5(a-c) IRATR(CM-1)=3420(N-H),3020(Ar-C-H),2915(Ali-C-H),1720(C=N),1570(C-N),1645(Ar-C=C),1440(N-N),1210(C-S),1095 
(Ar.C-Cl);1H-NMR(DMSO-d6,δppm):2.5(s,2H,NH),2.5-2.8(t,3H,N(CH3)2),6.6-6.8(m,9H,CH,Ar-H,diphenylamine);Electron 
absorption spectra (UV) λmax 334.6 (methanol). 
6(a-c) IR ATR(CM-1)=3420(N-H),3000(Ar-CH),2950(Ali-C-H),1540(C=N),1540(C-N),1550(N-N),1210(C-S),1H-NMR  (DMSO-
d6,δ ppm):2.1(t,3H,CH3,Aliph-H,dimethylamine),2.4(s,1H,NH),6.5-6.9(m,9H,CH,Ar-H,diphenylamine),7.2-7.4(m,Ar-
CH,C6H4);Electron absorption spectra (UV)λmax 315.8 (methanol). 
7(a-c) IR ATR(CM-1)=3130(N-H),3010(Ar-C-H),2096(Ali-CH)1660(C=N),1580(C-N),1510(Ar-C-C),1515(N-N);1H-NMR (DMSO-
d6,δ ppm):2.1(s,1H,NH),6.6(s,1H,CH,Aliph.-H,α- to C6H5)7.0-7.5(m,9H,CH,Ar-H,diphenylamine);Electron absorption 
spectra (UV) λmax 246.46 (methanol). 
8(a-c) IR ATR(CM-1)=3240(N-H),3060(Ar-C-H),2910(CH2),1620(C=N),1610(C-N),1540(Ar-C-C),1540(N-N),1486(C-O),1210(C-
S);1H-NMR (DMSO-d6, δ ppm):3.3(s,1H,NH),5.9(m,3H,CH,heter.-h,furan)  6.5-6.9(m,9H,CH,Ar-H,diphenylamine); 
Electron absorption spectra (UV)λmax 326.6 (methanol). 
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R2-substituted compunds (N-Mannich bases compounds ) 
Table 2 physiochemical properties of synthesized compounds. 
Comp. M.formula M.wt Rast’s 
M.wt. 
Depression 
of 
m.p.∆T(0C) 
B.P.[K] Log 
P 
MR[CM3/mol] HENRY’S 
LAW 
Gibbs 
Energy[kJ/mol] 
3a C25H25N7S2 488 484.9 81.87 1342.73 7.39 147.48 6.31 298.15 
3b C27H27N7OS2 530 532.5 74.55 1435.39 6.99 156.53 6.31 298.15 
3c C28H29N7S2 528 529.3 75.00 1431.32 8.12 159.4 6.31 298.15 
4a C25H25N7OS2 504 506.4 78.39 1423.35 7 149.29 6.31 298.15 
4b C27H27N7O2S2 546 544.3 72.94 1516.01 6.6 158.34 6.31 298.15 
4c C28H29N7OS2 544 546.8 72.63 1511.94 7.73 161.21 6.31 298.15 
5a C25H24ClN7S2 521.5 524.5 75.54 1385.14 7.95 152.08 6.31 298.15 
5b C27H26ClN7OS2 563.5 565.3 70.10 1477.8 7.55 161.13 6.31 298.15 
5c CH28H28ClN7S2 561.5 558.2 71.50 1473.73 8.68 164.01 6.31 298.15 
6a C27H30N8S2 531 533.5 74.42 1405.91 7.67 162.66 6.31 298.15 
6b C29H32N8OS2 573 570.1 69.63 1498.57 7.27 171.71 6.31 298.15 
6c C30H34N8S2 571 573.4 69.24 1494.5 8.41 174.58 6.31 298.15 
7a C27H27N7S2 514 513.5 77.31 1392.65 7.27 157.53 6.31 298.15 
7b C29H29N7OS2 556 558.6 71.07 1485.31 6.87 166.58 6.31 298.15 
7c C30H31N7S2 554 556.2 71.38 1481.24 8.01 169.58 6.31 298.15 
8a C23H23N7OS2 478 475.8 83.43 1320.49 6 140 6.31 298.15 
8b C25H25N7O2S2 520 518.1 76.62 1413.15 5.6 149.05 6.31 298.15 
8c C26H27N7OS2 518 521.1 76.19 1409.08 6.74 151.92 6.31 298.15 
 
Fig. 2 Three dimension structure of title compound with energy minima. 
 
 
Biological Evaluation 
1. Antimicrobial Activity (Pelczar J. M. et al., 2003 and 
Ananthanaryan R et al., 2005). 
 In an approach to develop and synthesised new 
antimicrobial and anti-inflammatory agents,derivatives of N-
Mannich bases of heterocyclic 1,3,4-thiadiazole 3(a-c),4(a-
c),5(a-c),6(a-c),7(a-c),8(a-c). 
 The in vitro antimicrobial activity of the 
synthesized compounds was screened by cup plate method 
against two gram positive bacteria viz. Staphylococcus 
aureus& Bacillus subtilis and two gram negative bacteria viz. 
Escherichia coli, Klebsiella pneumoniae and two pathogenic 
fungi Candida albicans, Aspergillus niger. The standard 
antibacterial agent used in the study was Ciprofloxacin, for 
the antifungal standard drug fluconazole. Twenty five 
milliliter of molten nutrient agar [ Sabouraud’s Dextrose 
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Agar (at pH 6.8)] was poured into pre sterilized Petri-dishes 
and allowed to solidify at room temperature. Broth cultures 
of the test microbial were used as inoculums under sterile 
conditions. Dimethyl formamide (DMF) was used as control 
and as solvent to prepare the stock solutions of the 
synthesized compounds. The concentration of the prepared 
stock solutions was 100 µg/ ml. Then 250µl of the stock 
solution was poured in to each cup, the Petri dishes were 
incubated at 250C 20C for 48 hours and were examined for 
zone of inhibition ( in mm) and % inhibition, exhibited by 
the test and standard compounds, which is given in Tables 3 
& 4. 
2. Anti-inflammatory Activity 
Carrageenin induced rat paw oedema model (Kulkarni 
S.K.,1999 and Winter C.A., et al., 1962) 
The anti-inflammatory activity of the standard drug 
diclofenac sodium and synthesized compounds, 3a, 3c,4b, 
5c,6a,6c,7b,8a, and 8c, was determined against 
carrageenan induced acute paw oedema in albino rats (66 
numbers weighing 200-225 g). The 1% w/v solution of 
carrageenan for injection was prepared in normal saline 
(0.9%NaCl) and 0.1 ml was injected underneath planter 
region. The 50 mg/kg dose of standard drug and synthesized 
compounds was administered in animals, by oral route using 
oral feeding tube through tuberculim syringe. The stock 
suspensions of standard and synthesized compounds were 
prepared in concentration of 10 mg/ml of 2% w/v CMC in 
distilled water. 
     The albino rats were weighed and marked and housed as 
six in a group. One group was for the standard drug 
(diclofenac sodium), one group served as control and the 
other groups were for the synthesized compounds. The hind 
paws (right and left) of the rats were marked just beyond 
tibio-tarsal junction. The initial paw volume (both right and 
left) of each rat was recorded by mercury displacement 
method using Plethysmograph. 
The control group was administered with normal saline 
(0.9% w/v NaCl)     (2.5 ml/kg) orally and other groups with 
respective drug suspension in CMS as per body weight. After 
30 minutes, 0.1 ml of 1% w/v solution of carrageenan in 
normal saline was injected using No. 26 gauge needle, in the 
planter region of the left paw of the rats. The right paw 
served as reference non-inflammed paw for comparison. The 
paw volume of both the legs of rats treated with control, 
standard and test compounds were recorded at 30, 60, and 
120 minutes after carrageenan challenge. 
The percent difference in the right and left paw volumes of 
each animal of control, standard and test compounds were 
calculated and meen percent change in paw volume in 
control, standard and test compounds treated animals were 
compared and expressed as percent ooedema inhibition of 
drug in Table 5 and percent oedema inhibition shown by the 
test and standard compounds are compared and expressed 
in Graph 3. 
 
Table 3 Results of in vitroantimicrobial activity of synthesized compunds 3-8(a-c) 
Comp. Gram +ve bacteria 
 
Gram –ve bacteria 
S. aureus B. subtilis E. coli K. Pneumoniae 
ZOI 
(mm) 
% 
Inhibition 
ZOI 
(mm) 
% 
Inhibition 
ZOI 
(mm) 
% 
Inhibition 
ZOI 
(mm) 
% 
Inhibition 
5a 12 52.17 18 85.71 10 43.47 16 69.56 
5b 19 82.60 20 95.23 08 34.78 15 65.21 
5c 06 26.08 08 38.09 14 60.86 13 56.52 
6a 19 82.60 12 57.14 12 52.17 13 56.52 
6b 15 65.21 06 28.57 08 34.78 06 26.08 
6c 04 17.39 14 66.66 06 26.08 14 60.86 
7a 04 17.39 12 57.14 06 26.08 14 60.86 
7b 16 69.56 10 47.61 06 26.08 10 43.47 
7c 06 26.08 06 28.57 08 34.78 12 52.17 
8a 09 39.13 08 38.09 08 34.78 10 43.47 
8b 12 52.17 08 38.09 12 52.17 06 26.08 
8c 05 21.73 12 57.14 08 34.78 09 39.13 
9a 05 21.73 06 28.57 12 52.17 15 65.21 
9b 03 13.04 08 38.09 08 34.78 15 65.21 
9c 12 52.17 06 28.57 14 60.86 15 65.21 
10a 06 26.08 06 28.57 08 34.78 11 47.82 
10b 08 34.78 12 57.14 10 43.47 13 56.52 
10c 06 26.08 06 28.57 16 69.56 09 39.13 
Standard 
(ciprofloxacin) 
23 100.00 21 100.00 23 100.00 23 100.00 
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Graph 1 Comparison of in vitro antibacterial activity exhibited by the test compounds 3-8(a-c) and standard drug 
ciprofloxacin  
 
 
Table 4 Results of in vitro antifungal activity of synthesized compunds 
Comp. A.niger C.albicans 
Zone of 
inhibition(mm) 
% inhibition Zone of 
inhibition(mm) 
% inhibition 
3a 13 68.42 05 31.25 
3b 10 52.63 06 37.50 
3c 11 57.89 08 50.00 
4a 18 94.73 15 93.75 
4b 10 52.63 17 106.25 
4c 11 57.89 04 25.00 
5a 14 73.68 09 56.25 
5b 11                   57.89 09 56.25 
5c 12 63.15 12 75.00 
6a 09 47.36 07 43.75 
6b 12 63.15 13 81.25 
6c 10 52.63 08 50.00 
7a 10 52.63 04 25.00 
7b 12 63.15 06 37.50 
7c 07 36.84 04 37.50 
8a 13 68.42 17 106.25 
8b 06 31.57 10 62.50 
8c 09 47.36 16 100.00 
Std(fluconazole) 19 100.00 16 100.00 
 
Graph 2 Comparison of the in vitro antifungal activity exhibited by the test compounds and standard drugs fluconazole 
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Anti-inflammatory activity 
Table 5 effect of test and standard compound on carrageenan-induced oedema 
Comp. Dose (mg/kg,p.o) Increase in paw volume (Mean±SEM)in ml at  
0.0 h 0.5 h 1.0 h 2.0 h 
Control(N/saline) 2.5/kg 0.0 0.83±0.13 1.25±0.13 1.73±0.13 
3a 50mg/kg 0.0 0.06±0.13** 0.36±0.13** 0.16±0.13** 
3c 50mg/kg 0.0 0.65±0.13* 0.16±0.13** 0.13±0.13** 
4b 50mg/kg 0.0 0.46±0.14** 0.28±0.14** 0.13±0.13** 
5c 50mg/kg 0.0 1.46±0.14 1.25±0.14 1.48±0.14 
6a 50mg/kg 0.0 1.46±0.14 1.95±0.13 1.16±0.13 
6c 50mg/kg 0.0 1.63±0.13 0.43±0.13 0.11±0.13 
7b 50mg/kg 0.0 0.4±0.13** 0.11±0.13** 0.0±0.13** 
8a 50mg/kg 0.0 1.5±0.13 1.23±0.14 0.6±0.13 
8c 50mg/kg 0.0 0.18±0.14** 0.51±0.13** 0.28±0.13* 
Std.(diclofenac) 50mg/kg 0.0 0.4±14** 0.2±0.13** 0.51±0.14** 
The statistical significance of differences assessed with an analysis of variance (ANOVA), followed by Bonferroni t-test 
test.Results are expressed in mean +_SEM. (N=6) significance levels *P<0.05 and **P<0.01, compared with control respectively. 
Graph 3 comparison results are expressed in mean ± SEM for statistical significance of differences of above compounds.  
 
 
RESULT AND DISCUSSION  
Antimicrobial activity. 
Derivatives of 1-methyl-4(5-(4-(phenyl amino) phenyl)-1, 
3,4-thiadiazol-2-e thiosemicar bazide (2a-f)were reacted 
with corresponding reactant dimity lamina, morph line and 
piper dine (a-c) in the presence of formaldehyde and 
concentrated  acid. All synthesized compounds were 
obtained in the range of 57.41-66.7%yield. Purity and 
homogeneity of the synthesized compound were routinely 
checked by sharp melting point and TLC. Melting point of the 
all synthesized compound was observes between at 240.0-
251.0-0c. 
57.41-66,7 %  yield purity and homogeneity  of the 
synthesized compound were routinely checked by sharp 
melting point and TLC .melting point of the all synthesized 
compounds was observed 240.0 t 251.0-0c . 
The in vitro antimicrobial activity of the synthesized 
compound was evaluated by cup plate method for bacteria 
viz. S. aurreus, B subtilis , E. coli, K. pneumonia and fungi c. 
albecans , A Niger .some compounds exhibited potent 
pharmacological activities as compared to the standard 
drugs. 
The compounds 3b and 4a exhibited highest activity i.e. each 
with 82.60% inhibition against  S. aureous  while the 
compound  4b , 5b, 6b, 7c showed 65.21, 69.56, 52.17 and  
52.17%  inhibition respectively against S. aureus.  Against B. 
subtiles the compound 3a, 3b, and 4c showed 85.71 , 95.23, 
66.66% inhibition respectively and were the highest activity 
compound. While the compound for 4a, 5a, 6c, 8b(each with 
57.41% inhibition ) and 5b (47.61% inhibition )showed 
activity. 
When tested against E.coli the compound 3c, 4a, 6b, 7a and 
7c exhibited 60.86, 52.17,52.17,52.17 and 60.86% inhibition 
respectively and these compound showed Good activity 
among the tested compound. The highest activity was 
observed with 8c (with 69.56% inhibition). 
Against K. pneumoniae the compound 3b 
(65.21%),4c(60.86% inhibition), 5a (60.86% inhibition), 7a 
(65,21% inhibition), 7b (65.21% inhibition)  and 7c (65.21% 
inhibition) exhibited good activity. Among the highest ac 
tested compounds 3a(69.56%)showed activity. 
All the synthesized compound were screened in vitro against 
the pathogenic fungal strains A.niger and c.albicans. The 
compound 3a (68.42% inhibition), 5a (73.68% inhibition), 
5c (63.15 inhibition), 6b, 7b (each with 63.15% inhibition) 
and 8a (68.42% inhibition) showed excellent activities. 
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The anti-inflammatory activity of the selected compound 3a 
,3c, 4b, 5c ,6a, 6c, 7b, 8a and 8c was screened by carrageen 
induced rat paw oedema method against the standard drug 
diclofenac sodium. The activity was evaluated over a time 
frame of 2h, after the carrageen challenge, at intervals of 0.5 
h., 1.0 h. and 2.o 0.5 h. 
After 0.5 h, the compound 3a,7b and 8c showed 92.77,51.80 
and 78.31% oedema inhibition as compared to 51.80% 
oedema inhibition shown by the standard drug diclofenac 
sodium. the data indicate the short onset of action and 
comparable activity of these compound. 
The standard drug declofenac sodium showed the maximum 
anti-inflammatory activity (84.00% oedema inhibition). 
comparable activity at this time interval was exhibited by 
the compound 3a (71.2% oedema inhibition), 3c (87.2% 
oedema inhibition), 4b (77.6% oedema inhibition) and 7b 
(91.2% oedema inhibition). 
At 2.0 h time interval 3a,3c,4b,6c,7b, and 8c exhibited 
90.75,92.48,92.48,93.64,100 and 83.81% oedema inhibition 
respectively in comparison to 70.52% oedema inhibition 
shown by the standard drug. in brief compound 3a and 7b 
showed excellent anti-inflammatory activity at time interval 
of 0.5,1.0 and 2.0 h. 
Statistical Analysis 
Table 5 result are expressed as mean±standard error of 
mean (SEM) of at least 6 animals per group. Statistical 
significance of differences between group was determined 
by one-way analysis of variance (ANOVA) followed by 
bonfeeroni t-test. For the statistical determination, statistical 
computerized software SIGMASTAT was used. 
Statistical analysis was assessed for the test compound 3a, 
3c, 4b, 6a, 7b, 8a & 8c compare with control respectively. In 
pharmacological study anti-inflammatory effect of 
synthesized compounds were observed and found to be 
statically significant at the levels *P<0.05 and **P<0.01 
compared with control normal saline treated animals’ group. 
Probability value less than 0.01 (P<0.01) was significant. 
Test compound 3a, 3c, 4b, 7b and 8c showed significant 
decrease in oedema on rat’s paw compared with the test 
compound 5c, 6a, 6c and 8a at significance level. The Fcal 
(6.98933)>Ftab(4.8317) hence there is a statistically 
significant difference (P<0.01) in the mean values of the 
treated groups .The test compound 3a,3c,4b,7band8c found 
as significant compound .However, the profile of compound 
was at the expected level.  
SUMMARY AND CONCLUSION 
In summary, designed and synthesized a series of N-Mannich 
bases of heterocyclic 1,3,4-thiadiazole 3-8(a-c) and 
characterization of the synthesized compound was carried 
was carried out by determining their melting points, Rf value 
,UV,IR, Spectra, 1H-NMR and evaluated for in-vitro anti-
microbial and ant-inflammatory activities .The compound 3b 
and 4a showed highest activities against S. aureus while the 
compound 3a and 3b were highly active  against B.subtilis. It 
revealed that compound 3b exhibited excellent activity 
against both bacteria. The compounds 3c, 7c and 8c showed 
very comparable activity as compare to the standard drug 
ciprofloxacin against the pathogen E.coli. It can be assumed 
that pipiridine ring is necessary in mannich base for 
antibacterial activity against Gram-negative E.coli. 
The compound 3a was observed as the most active against K. 
pneumoniae. The in vitro antifungal activity of the 
synthesized compounds was also evaluated by cup-plate 
method.The study revealed that the compounds 3a,4a,5a and 
8a are the most active against the fungi A.niger .Attribution 
of structure dimethylamine group is necessary in Mannich 
base compounds for antifungal activity against A.niger. 
When compard with the standard drug Fluconazole, the 
compounds 4a,4b, 5c,6b,8a and 8c showed excellent activity 
against the fungi C.albicans. 
The anti-inflammatory activity of the randomly selected 
compounds was evaluated, on albino rats, by carrageen 
induced rat paw oedema method using the standard drug 
diclofenac sodium. The study was carried out over a frame of 
2h at intervals of 0.5, 1.0and 2.0h. Fluconazole, the 
compounds 3a,4b,7b and 8c possess more potent anti-
inflammatory activity compared with the standard drug. 
To summarize the overall performance, the compound 7b 
exhibited excellent anti-inflammatory pharmacological 
activity. Structurally the compound 7b has a greater number 
of unsaturated hydrocarbons in Schiff base which shows 
good lipophilic properties with electron rich morpholine 
ring in Mannich base.  
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